Recursion Pharmaceuticals Inc has 10 Schedule 13D or 13G filings on record since 2025-12-23. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 8.5% | 44,541,605 | SCHEDULE 13G/A, 2026-07-29 | 2026-06-30 |
| ARK Investment Management LLC | 7.25% | 37,316,856 | SCHEDULE 13G/A, 2026-02-03 | 2025-12-31 |
| State Street Corporation | 6.6% | 34,706,130 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| Vanguard Portfolio Management | 5.97% | 31,369,274 | SCHEDULE 13G, 2026-07-31 | 2026-06-30 |
| Vanguard Capital Management | 5.09% | 26,744,129 | SCHEDULE 13G, 2026-07-31 | 2026-06-30 |
| Baillie Gifford & Co | 4.6% | 23,774,972 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 |
| Mubadala Investment Co PJSC | 1.4% | 0 | SCHEDULE 13D/A, 2025-12-23 | 2024-11-20 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Purpose of Transaction (Item 4)
Mubadala Investment Co PJSC
On March 31, 2023, MIC LP transferred the 1,388,889 Common Shares that it then held to MCAS. As a result, as of such time, MCAS directly held 1,388,889 Common Shares and MIC LP ceased to beneficially own any Common Shares. In addition, the Issuer and Exscientia plc, a public limited company incorporated under the laws of England and Wales ("Exscientia"), entered into a transaction agreement, dated as of August 8, 2024, as amended (the "Transaction Agreement"). The Transaction Agreement provided that, subject to the conditions set forth therein, the Issuer would acquire the entire issued and to be issued share capital of Exscientia pursuant to a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme of Arrangement" and such transaction, the "Transaction"). The Transaction closed on November 20, 2024. Under the Transaction Agreement, pursuant to and following the effective time of the Scheme of Arrangement (the "Effective Time"), each ordinary share in Exscientia (each an "Exscientia Share") was automatically acquired by the Issuer in exchange for 0.7729 Common Shares. Accordingly, at the Effective Time, MIC Europe received, in exchange for the 1,542,600 Exscientia Shares that it then held, 1,192,275 Common Shares. As a result, at the Effective Time, MIC Europe directly held 1,192,275 Common Shares and MIC UK beneficially owned 2,581,164 Common Shares. In addition, between December 18, 2025, and the date hereof, Fifteenth sold a total of …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-12-23; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-23 | Mubadala Investment Co PJSC | 1.4% | SCHEDULE 13D/A |
| 2026-02-03 | ARK Investment Management LLC | 7.25% | SCHEDULE 13G/A |
| 2026-02-05 | Baillie Gifford & Co | 4.6% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-24 | BlackRock, Inc. | 7.2% | SCHEDULE 13G/A |
| 2026-05-12 | State Street Corporation | 5.5% | SCHEDULE 13G |
| 2026-07-29 | BlackRock, Inc. | 8.5% | SCHEDULE 13G/A |
| 2026-07-31 | Vanguard Capital Management | 5.09% | SCHEDULE 13G |
| 2026-07-31 | Vanguard Portfolio Management | 5.97% | SCHEDULE 13G |
| 2026-08-07 | State Street Corporation | 6.6% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Recursion Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.